Work

A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system

Year: 2013

Type: article

Abstract: Bispecific T-cell engagers (BiTEs) may break multiple barriers that currently limit the use of immunotherapy in glioblastoma patients. We have recently described a novel BiTE specific for a mutated form of the epidermal growth factor receptor, EGFRvIII, that exerts potent antineoplastic effects against established invasive tumors of the brain.

Source: OncoImmunology

DOI: 10.4161/onci.23639

Authors: Bryan D. Choi, Ira Pastan, Darell D Bigner, John H. Sampson

Institutions: Duke University, Duke Medical Center, National Institutes of Health, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913